Physician profile
Pujyitha Mandiga
NPI 1740771401
$2,640.69
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.48 · 2021: $209 · 2022: $789 · 2023: $1,049 · 2024: $580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,479 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,479.13 |
| Education | $149.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,049.17 | 2021-2024 | |
| Janssen Biotech, INC. | $391.93 | 2022-2024 | Stelara, Tremfya |
| E.R. Squibb & Sons, L.L.C. | $234.19 | 2022-2023 | Zeposia |
| Gilead Sciences, INC. | $137.35 | 2024 | Epclusa |
| Ardelyx, INC. | $130.20 | 2023 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $119.70 | 2023 | Terlivaz |
| Takeda Pharmaceuticals U.S.A., INC. | $110.17 | 2022-2024 | Entyvio |
| Erbe USA INC | $90.00 | 2023 | Erbe Vio3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.68 | 2022-2023 | Xifaxan, Plenvu |
| Merck Sharp & Dohme LLC | $63.88 | 2021-2022 | |
| Qol Medical, LLC | $63.65 | 2023 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $46.53 | 2022-2023 | Dupixent |
| Braintree Laboratories, INC. | $28.81 | 2022 | |
| Amgen INC. | $20.07 | 2023 | Amjevita, Avsola |
| Janssen Scientific Affairs, LLC | $17.84 | 2024 | Stelara |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $17.09 | 2021 | |
| Vivus LLC | $15.85 | 2022 | |
| W. L. Gore & Associates, INC. | $14.10 | 2023 | Gore Cardioform Septal Occluder |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pujyitha Mandiga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.